Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.

Anita Turk, MD, discusses the unmet needs that still exist in the realm of colorectal cancer treatment and management.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Mack Roach III, MD, discusses the development and evaluation of a multimodal AI algorithm designed to predict prostate cancer outcomes and its performance across racial subgroups.

Anita Turk, MD, discusses abstracts from ASCO 2025 highlight the evolving role of ctDNA in the management of colorectal ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Antonio Jimenez Jimenez, MD, discusses the ACCESS trial of PTCy-based GVHD prophylaxis after mismatched unrelated donor stem ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Joseph Jacob, MD, discusses the promising impact of TAR-200.

Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists discuss how successful treatment of locally advanced anal cancer requires a multidisciplinary approach involving ...